School spin-out Exscientia announces €250M collaboration agreement with Sanofi
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease. Exscientia is a spin-out company from the School.